These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1113 related articles for article (PubMed ID: 20306678)
21. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. Metzeler KH; Dufour A; Benthaus T; Hummel M; Sauerland MC; Heinecke A; Berdel WE; Büchner T; Wörmann B; Mansmann U; Braess J; Spiekermann K; Hiddemann W; Buske C; Bohlander SK J Clin Oncol; 2009 Oct; 27(30):5031-8. PubMed ID: 19752345 [TBL] [Abstract][Full Text] [Related]
22. Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome. Iriyama N; Asou N; Miyazaki Y; Yamaguchi S; Sato S; Sakura T; Maeda T; Handa H; Takahashi M; Ohtake S; Hatta Y; Sakamaki H; Honda S; Taki T; Taniwaki M; Miyawaki S; Ohnishi K; Kobayashi Y; Naoe T Ann Hematol; 2014 Jun; 93(6):957-63. PubMed ID: 24441947 [TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607 [TBL] [Abstract][Full Text] [Related]
24. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia. Fuster O; Barragán E; Bolufer P; Such E; Valencia A; Ibáñez M; Dolz S; de Juan I; Jiménez A; Gómez MT; Buño I; Martínez J; Cervera J; Montesinos P; Moscardó F; Sanz MÁ Ann Hematol; 2012 Jan; 91(1):1-7. PubMed ID: 21538063 [TBL] [Abstract][Full Text] [Related]
25. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia. Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998 [TBL] [Abstract][Full Text] [Related]
26. BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis. Eid MA; Attia M; Abdou S; El-Shazly SF; Elahwal L; Farrag W; Mahmoud L Int J Lab Hematol; 2010 Apr; 32(2):197-205. PubMed ID: 19555438 [TBL] [Abstract][Full Text] [Related]
27. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735 [TBL] [Abstract][Full Text] [Related]
28. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk. Park SH; Chi HS; Cho YU; Jang S; Park CJ Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719 [TBL] [Abstract][Full Text] [Related]
29. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448 [TBL] [Abstract][Full Text] [Related]
31. Low MDR1 and BAALC expression identifies a new subgroup of intermediate cytogenetic risk acute myeloid leukemia with a favorable outcome. Guo X; Shi P; Chen F; Zha J; Liu B; Li R; Dong H; Zheng H; Xu B Blood Cells Mol Dis; 2014 Sep; 53(3):144-8. PubMed ID: 24855032 [TBL] [Abstract][Full Text] [Related]
32. [Clinical characteristics and therapeutic efficacy of normal karyotype AML patients with CEBPA mutation]. Du YZ; Su L; Li W; Yu P; Tan YH; Lin H; Gao SJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):16-9. PubMed ID: 24598643 [TBL] [Abstract][Full Text] [Related]
33. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations. Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865 [TBL] [Abstract][Full Text] [Related]
34. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia]. Ruan M; Zhang L; Han C; Liu X; Ai X; Zhang J; Liu T; Yang W; Chen X; Guo Y; Wang S; Li Q; Zou Y; Chen Y; Zhu X Zhonghua Er Ke Za Zhi; 2014 Apr; 52(4):303-7. PubMed ID: 24915920 [TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype. Marjanovic I; Karan-Djurasevic T; Kostic T; Virijevic M; Vukovic NS; Pavlovic S; Tosic N Int J Lab Hematol; 2021 Jun; 43(3):433-440. PubMed ID: 33242229 [TBL] [Abstract][Full Text] [Related]
36. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798 [TBL] [Abstract][Full Text] [Related]
37. Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients. Ahmad F; Rajput S; Mandava S; Das BR Genet Test Mol Biomarkers; 2012 Jul; 16(7):707-15. PubMed ID: 22731647 [TBL] [Abstract][Full Text] [Related]
38. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML. Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH Eur J Haematol; 2013 Aug; 91(2):112-21. PubMed ID: 23672350 [TBL] [Abstract][Full Text] [Related]
39. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Langer C; Marcucci G; Holland KB; Radmacher MD; Maharry K; Paschka P; Whitman SP; Mrózek K; Baldus CD; Vij R; Powell BL; Carroll AJ; Kolitz JE; Caligiuri MA; Larson RA; Bloomfield CD J Clin Oncol; 2009 Jul; 27(19):3198-204. PubMed ID: 19451432 [TBL] [Abstract][Full Text] [Related]
40. BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Zhang J; Shi J; Zhang G; Zhang X; Yang X; Yang S; Wang J; Ke X; Fu L Ann Hematol; 2018 Aug; 97(8):1391-1397. PubMed ID: 29696374 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]